B. Killing

443 total citations
9 papers, 329 citations indexed

About

B. Killing is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, B. Killing has authored 9 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in B. Killing's work include Colorectal Cancer Treatments and Studies (7 papers), Gastric Cancer Management and Outcomes (4 papers) and Genetic factors in colorectal cancer (3 papers). B. Killing is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Gastric Cancer Management and Outcomes (4 papers) and Genetic factors in colorectal cancer (3 papers). B. Killing collaborates with scholars based in Germany, United States and Portugal. B. Killing's co-authors include Ullrich Graeven, Axel Hinke, Dirk Arnold, Salah‐Eddin Al‐Batran, Thoralf Lange, Christian Lerchenmüller, Reinhard Depenbusch, Susanna Hegewisch‐Becker, Georg Dietrich and Hans‐Joachim Schmoll and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

B. Killing

8 papers receiving 322 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Killing Germany	7	288	141	57	51	48	9	329
Nicolas Sommer United States	11	260 0.9×	107 0.8×	42 0.7×	107 2.1×	74 1.5×	27	356
J.-L. Canon Belgium	7	288 1.0×	105 0.7×	122 2.1×	29 0.6×	30 0.6×	16	334
W. Brückl Germany	10	198 0.7×	163 1.2×	44 0.8×	56 1.1×	53 1.1×	27	329
Nathalie Aucoin Canada	10	310 1.1×	146 1.0×	30 0.5×	46 0.9×	23 0.5×	29	348
Jan-Henrik Terwey United Kingdom	8	264 0.9×	104 0.7×	51 0.9×	114 2.2×	69 1.4×	20	302
Philippe Ronga Germany	6	180 0.6×	79 0.6×	21 0.4×	38 0.7×	37 0.8×	13	251
Karen Soussan-Lazard France	9	276 1.0×	108 0.8×	22 0.4×	38 0.7×	123 2.6×	11	336
R. K. Ramanathan United States	11	292 1.0×	103 0.7×	35 0.6×	25 0.5×	43 0.9×	32	370
Javier Sastre Valera Spain	6	288 1.0×	126 0.9×	82 1.4×	49 1.0×	100 2.1×	15	348

Countries citing papers authored by B. Killing

Since Specialization

Citations

This map shows the geographic impact of B. Killing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Killing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Killing more than expected).

Fields of papers citing papers by B. Killing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Killing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Killing. The network helps show where B. Killing may publish in the future.

Co-authorship network of co-authors of B. Killing

This figure shows the co-authorship network connecting the top 25 collaborators of B. Killing. A scholar is included among the top collaborators of B. Killing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Killing. B. Killing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Hegewisch‐Becker, Susanna, Axel Hinke, Ullrich Graeven, et al.. (2018). Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. European Journal of Cancer. 101. 105–113. 18 indexed citations

Quidde, Julia, Susanna Hegewisch‐Becker, Ullrich Graeven, et al.. (2016). Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. Annals of Oncology. 27(12). 2203–2209. 18 indexed citations

Quidde, Julia, Ullrich Graeven, C. Lerchenmueller, et al.. (2016). Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial. Annals of Oncology. 27. vi184–vi184.

Jordan, Karin, Tim Luetkens, C. Gog, et al.. (2016). Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study – AIO SUP-0108. European Journal of Cancer. 63. 127–134. 20 indexed citations

Hegewisch‐Becker, Susanna, Ullrich Graeven, Christian Lerchenmüller, et al.. (2015). Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. The Lancet Oncology. 16(13). 1355–1369. 176 indexed citations

Hegewisch-Becker, S., Ullrich Graeven, Christian Lerchenmüller, et al.. (2014). Maintenance Strategy with Fluoropyrimidines (Fp) Plus Bevacizumab (Bev), Bev Alone or No Treatment, Following a 24-Week First-Line Induction with Fp, Oxaliplatin (Ox) and Bev for Patients with Metastatic Colorectal Cancer: Mature Data and Subgroup Analysis of the Aio Krk 0207 Phase III Study. Annals of Oncology. 25. iv167–iv167. 7 indexed citations

Quidde, Julia, Dirk Arnold, S. Hegewisch-Becker, et al.. (2014). Quality of Life (Qol) in Patients with Metastatic Colorectal Cancer (Mcrc) Receiving Maintenance Therapy After First-Line Inductive Treatment: a Qol Sub-Analysis of the Aio Krk 0207 Phase III Trial. Annals of Oncology. 25. iv177–iv177. 1 indexed citations

Graeven, Ullrich, B. Kremer, B. Killing, et al.. (2006). Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. British Journal of Cancer. 94(9). 1293–1299. 83 indexed citations

Graeven, U., Ida Vogel, B. Killing, et al.. (2004). Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer. Journal of Clinical Oncology. 22(14_suppl). 3061–3061. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact